DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07297238

RecruitingPhase NA

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Therapeutic Efficacy of GLP-1 on Intestinal Barrier Function in Patients With Short Bowel Syndrome and Intestinal Failure: A Preliminary Randomized Controlled Trial

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

2

Recruiting sites

2

Enrollment

20

estimated

Study population

Gastrointestinal (gastroparesis / short bowel / pancreatitis)

Key I/E criterion

—

Primary endpoint

•Serum Biomarkers of Intestinal Barrier Function

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07297238
Org study ID2025-09-17

Timeline

Milestones

Study first posted2025-12-22actual
Study start2026-01-24actual
Primary completion2026-05-27actual
Last update posted2026-05-28actual
Study completion2026-06-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-allSemaglutide

Study populations

Who this study enrolls

Gastrointestinal (gastroparesis / short bowel / pancreatitis)

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Participants voluntarily provided written informed consent for this trial;
•Aged 18 to 80 years, inclusive, regardless of gender;
•With stable vital signs;
•Diagnosis of SBS-IF, confirmed by existing medical/surgical records, receiving parenteral nutrition (PN) due to surgical resection of the small intestine (<200 cm from the duodenojejunal flexure), and meeting one of the following criteria:
–Colon continuity maintained without jejunal/ileal stoma (Type II or III);
–Presence of a jejunostomy or ileostomy (Type I);
•Expected requirement of PN for more than 4 weeks, with an average PN caloric intake ≥80%;
•Ability to comply with the medication dosing and visit schedule;
•Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively;
•No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection;
•No history of drug abuse;
•Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants);
•No participation in any other drug trials (including the investigational product in this study) within three months prior to enrollment.

Exclusion criteria

•Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator;
•Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation;
•History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product;
•Patients with malignancy at any site;
•Those with psychiatric disorders, inability to cooperate, or impaired consciousness;
•Patients with contraindications to the investigational drug (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2);
•Immunodeficiency, or current use of immunosuppressants or corticosteroids;
•Immediate family members of the sponsor, investigator, or study staff directly involved in the trial;
•Any other condition considered by the investigator as grounds for exclusion.

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
5
Patient-reported / QoL
1
Other clinical outcomes
1

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Quality of life score

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

SF-36 total

change from baseline, improvement

Other clinical outcomes

1 endpoint
Secondary/protocol endpoint

PN Liberation Rate

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

threshold achievement, improvement

Other (unclassified)

5 endpoints
Primary/protocol endpoint/low confidence

Serum Biomarkers of Intestinal Barrier Function

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Intestinal absorption of nutrients (protein)

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Intestinal absorption of nutrients (carbohydrate)

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

descriptive

Secondary/protocol endpoint/low confidence

Intestinal absorption of nutrients (fat)

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

descriptive

Secondary/protocol endpoint/low confidence

Nutritional status indicator

Time frame:the initiation of enrollment and upon completion of the 28-days treatment period

change from baseline, descriptive

Publications (14)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.